Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.
Aranda E, Viéitez JM, Gómez-España A, Gil Calle S, Salud-Salvia A, Graña B, Garcia-Alfonso P, Rivera F, Quintero-Aldana GA, Reina-Zoilo JJ, González-Flores E, Salgado Fernández M, Guillén-Ponce C, Garcia-Carbonero R, Safont MJ, La Casta Munoa A, García-Paredes B, López López R, Sastre J, Díaz-Rubio E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Aranda E, et al. Among authors: lopez lopez r. ESMO Open. 2020 Nov;5(6):e000944. doi: 10.1136/esmoopen-2020-000944. ESMO Open. 2020. PMID: 33148620 Free PMC article. Clinical Trial.
A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer.
Barbazán J, Vieito M, Abalo A, Alonso-Alconada L, Muinelo-Romay L, Alonso-Nocelo M, León L, Candamio S, Gallardo E, Anido U, Doll A, de los Ángeles Casares M, Gómez-Tato A, Abal M, López-López R. Barbazán J, et al. Among authors: lopez lopez r. J Cell Mol Med. 2012 Oct;16(10):2342-9. doi: 10.1111/j.1582-4934.2012.01544.x. J Cell Mol Med. 2012. PMID: 22304365 Free PMC article.
Molecular characterization of circulating tumor cells in human metastatic colorectal cancer.
Barbazán J, Alonso-Alconada L, Muinelo-Romay L, Vieito M, Abalo A, Alonso-Nocelo M, Candamio S, Gallardo E, Fernández B, Abdulkader I, de Los Ángeles Casares M, Gómez-Tato A, López-López R, Abal M. Barbazán J, et al. Among authors: lopez lopez r. PLoS One. 2012;7(7):e40476. doi: 10.1371/journal.pone.0040476. Epub 2012 Jul 10. PLoS One. 2012. PMID: 22811761 Free PMC article.
A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Barbazán J, Muinelo-Romay L, Vieito M, Candamio S, Díaz-López A, Cano A, Gómez-Tato A, Casares de Cal Mde L, Abal M, López-López R. Barbazán J, et al. Among authors: lopez lopez r. Int J Cancer. 2014 Dec 1;135(11):2633-43. doi: 10.1002/ijc.28910. Epub 2014 Apr 29. Int J Cancer. 2014. PMID: 24752533 Free article.
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Borrero-Palacios A, et al. Among authors: lopez lopez r. Sci Rep. 2019 Feb 22;9(1):2589. doi: 10.1038/s41598-019-39291-2. Sci Rep. 2019. PMID: 30796344 Free PMC article. Clinical Trial.
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J. Borrero-Palacios A, et al. Among authors: lopez lopez r. Sci Rep. 2019 May 17;9(1):7706. doi: 10.1038/s41598-019-43809-z. Sci Rep. 2019. PMID: 31097738 Free PMC article.
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study.
Sastre J, García-Alfonso P, Viéitez JM, Cano MT, Rivera F, Reina-Zoilo JJ, Salud-Salvia A, Quintero G, Robles-Díaz L, Safont MJ, La Casta A, Gil S, Polo E, Asensio-Martínez E, García-Paredes B, López RL, Guillot M, Valladares-Ayerbes M, Aranda E, Díaz-Rubio E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Sastre J, et al. Among authors: lopez rl. ESMO Open. 2021 Apr;6(2):100062. doi: 10.1016/j.esmoop.2021.100062. Epub 2021 Mar 10. ESMO Open. 2021. PMID: 33711671 Free PMC article. Clinical Trial.
257 results